The FDA approves Johnson & Johnson's Darzalex Faspro for high-risk smoldering multiple myeloma and Caplyta as an add-on ...

During a live event, Thomas G. Martin, MD, discussed updated findings from the CARTITUDE-1 trial of cilta-cel and what they signify for patients with no disease progression at 5 years.

A new option is now approved to treat adults living with high-risk smoldering multiple myeloma (MM). 1 The FDA has greenlit ...

This approval marks a milestone for high-risk sMM patients, but analyst Biswajit Podder notes that there are caveats to its ...

Johnson & Johnson (NYSE:JNJ) today announced the U.S. Food and Drug Administration (FDA) approved DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) as a single agent treatment for adult patients ...

The FDA approved Darzalex Faspro for the treatment of adults with high-risk smoldering multiple myeloma. The U.S. Food and ...

Darzalex Faspro improved PFS and OS in high-risk smoldering multiple myeloma, reducing progression or death risk by 51% and death risk by 48%. The AQUILA study showed a superior overall response rate ...

Support for first and only high-risk smouldering multiple myeloma treatment came from positive phase 3 trial results ...

The FDA on Thursday approved daratumumab-hyaluronidase (Darzalex Faspro) as the first drug for high-risk smoldering multiple ...

For the first time, patients with abnormal cells detected in their bone marrow have a treatment option before the condition ...

Darzalex Faspro’s approval for smoldering multiple myeloma could allow for earlier intervention and reduce the risk of ...

The approval for HR-SMM was based on data from the phase 3 AQUILA study, which evaluated Darzalex Faspro in adults aged 31 years and older with HR-SMM.